Sitagliptin is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl
peptidase-4 (DPP-4) inhibitor class. It was developed, and is marketed, by Merck
Easy to read patient leaflet for sitagliptin. Includes indications, proper use, special
instructions, precautions, and possible side effects.
Get information on JANUVIA® (sitagliptin) tablets and information to help
manage type 2 diabetes from the official Web site for JANUVIA.
Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl
peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be
Sitagliptin | C16H15F6N5O | CID 4369359 - structure, chemical names, physical
and chemical properties, classification, patents, literature, biological activities, ...
Sitagliptin is an antidiabetic used to treat diabetes. Read about sitagliptin and it's
side effects and dosage information online at Patient.
Mar 14, 2016 ... However, because sitagliptin is primarily renally eliminated, severe hepatic
impairment is not expected to affect the pharmacokinetics of ...
Dec 24, 2014 ... Read about Januvia (sitagliptin), the diabetes medication that reduces blood
sugar levels in individuals with type 2 diabetes.
May 16, 2016 ... Sitagliptin is an oral diabetes medicine that helps control blood sugar levels. It
works by regulating the levels of insulin your body produces after ...
Jul 15, 2015 ... Sitagliptin, the first in a new class of diabetic drugs called dipeptidyl peptidase-4 (
DPP-4) inhibitors, is approved as an adjunct to diet and ...